Disease Overview：Lung Cancer（LC）
Lung cancer, a malignant neoplasm originating in bronchial epithelial cells or pulmonary parenchyma, remains the leading cause of cancer-related mortality worldwide. It is broadly classified into non-small cell lung cancer (NSCLC)—including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—and small cell lung cancer (SCLC), each with distinct histopathological features, molecular profiles, and therapeutic implications. Early-stage disease may be asymptomatic; later presentations often include persistent cough, hemoptysis, dyspnea, or systemic symptoms such as weight loss and paraneoplastic syndromes. Diagnosis relies on high-resolution CT imaging, PET-CT staging, bronchoscopy with biopsy, and comprehensive molecular testing—including EGFR, ALK, ROS1, BRAF, RET, MET, and PD-L1 expression—to guide targeted therapy or immunotherapy selection.
China offers compelling advantages for international patients seeking lung cancer care. Its oncology centers—many accredited by international bodies such as JCI—house world-class thoracic oncologists trained in multidisciplinary tumor boards and early-phase clinical trials. Advanced technologies including robotic-assisted VATS, 4D radiotherapy (e.g., TrueBeam STx), liquid biopsy platforms, and next-generation sequencing are widely deployed. Five-year survival rates for stage I–II NSCLC exceed 70% in top-tier hospitals, supported by robust real-world evidence from national registries. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory compliance.
As a dedicated medical tourism agency, we facilitate seamless access to these resources: vetting accredited hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, arranging visas and accommodation, and providing bilingual case management—from initial diagnostics through follow-up care.
Lung Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Lung Cancer (Oncology Department)
Non-Surgical / Medical Therapies
*Eligibility*: Confirmed NSCLC or SCLC diagnosis; molecular profiling (EGFR/ALK/ROS1/BRAF/PD-L1) required for targeted/immunotherapy.
- •Targeted Therapy (e.g., Osimertinib, Alect *Criteria*: EGFR-mutated (exon 19 del/L858R) or ALK+ advanced NSCLC
- *Molecular testing (NGS panel)*: $280–$410 - *Monthly monitoring (CT chest + blood tests)*: $190
- •Immunotherapy (e.g., Pembrolizumab, Camrelizumab)
- *Per infusion (3-week cycle)*: $1,100–$1,750 (Tier 1: domestic PD-1 inhibitor; Tier 2: imported) - *Baseline PET-CT*: $480 - *Liver/kidney function + CBC per cycle*: $45
- •Chemotherapy (Platinum-doublet: Paclitaxel + Carboplatin)
- *Per 3-week cycle*: $320–$510 (generic IV agents) - *Pre-cycle labs (CBC, renal/hepatic panel)*: $65
Surgical / Interventional Therapies
*Eligibility*: Clinical stage I–IIIA NSCLC; adequate pulmonary reserve (FEV1 >1.5 L, DLCO >50%); no distant metastasis on staging workup.
- •Lobectomy (VATS or robotic-assisted)
- *Preoperative workup*: $380 (CT angiography + pulmonary function test + ECG + routine labs) - *Post-op pathology + IHC*: $160
- •Sublobar Resection (Wedge/Segmentectomy)
- *Same preoperative workup*: $380
- •SBRT (Stereotactic Body Radiotherapy)
- *Simulation CT + 4D motion management*: $320
Special/Complex Condition Management
- •Oligometastatic Disease (≤3 mets, lung + adrenal/bone/brain):
- •Malignant Pleural Effusion:
- *Pleurodesis (talc slurry)*: $890
- •Brain Metastases (symptomatic):
- *SRS (single-session)*: $2,300–$3,400
Quick Selection Guide
- •<65 years, fit, stage IA: VATS lobectomy ($4,200–$6,900) — curative intent, lowest recurrence risk.
- •75+ years, COPD/CHF, stage IB: SBRT ($2,800–$4,300) — avoids surgical morbidity, equivalent local control.
- •Stage IV, EGFR+: Osimertinib ($420/month) + NGS ($280) — superior PFS vs. chemo, outpatient.
- •Budget-constrained, PD-L1 high: Domestic PD-1 inhibitor ($1,100/infusion) — 30–40% lower than imported equivalents.
- •Stage III unresectable: Concurrent chemoradiation** ($5,100–$7,800) — standard of care, includes 30-fraction RT + 2 cycles chemo.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Lung Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Lung Cancer treatment with China top medical destinations:
